Durability of glycemic control using U-500 insulin

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Short-term studies indicate U-500 insulin improves glycemic control but may cause significant weight gain.
• Limited data exists on the long-term glycemic durability and weight change patterns associated with U-500 insulin use.

Purpose of the Study:

• To assess the sustained glycemic control (durability) of U-500 insulin in highly insulin-resistant individuals.
• To determine if weight gain associated with U-500 insulin use is continuous or stabilizes over time.

Main Methods:

• Retrospective chart review of 53 patients using U-500 insulin, with data analyzed for up to 3 years before and after initiation.
• Detailed review of physical and metabolic data, including HbA1c, insulin dosage, body weight, and hypoglycemia symptoms.
• Analysis focused on patients with at least 3 years of follow-up data (n=20).

Main Results:

• U-500 insulin use resulted in a sustained ~1% decrease in HbA1c within 3-6 months, maintained for up to 3 years.
• Patients experienced an ~80% increase in insulin dose and ~10 lbs weight gain in the first 6-12 months, with a temporary spike in hypoglycemia.
• Insulin doses, body weight, glycemic control, and hypoglycemia symptoms stabilized after the initial titration period.

Conclusions:

• U-500 insulin provides sustained glycemic control in a clinical setting for highly insulin-resistant patients.
• Glycemic improvements are durable for up to 3 years, following an initial phase of insulin titration and weight gain.
• Weight gain and insulin dose requirements stabilize after the first year, supporting long-term U-500 insulin utility.